H.C. Wainwright raised the firm’s price target on Kamada (KMDA) to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a “long over-hanging distraction that was unlikely to be fruitful.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMDA:
- Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.
- Kamada Discontinues Phase 3 Inhaled AAT Trial, Projects Growth in 2026
- Kamada discontinues Phase 3 inhaled AAT clinical trial
- Kamada reiterates FY25 revenue guidance $178M-$182M
- Kamada’s Growth Potential and Strategic Development Justify Buy Rating